[177Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies
Amanda Gustafsson, Hedvig Svedberg, Sara S Rinne, Filippa Bertilsson, Ram Kumar Selvaraju, Anja C Lundgren Mortensen, Cecilia Lindskog, Marika Nestor · 2026
Read [177Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies by Amanda Gustafsson, Hedvig Svedberg, Sara S Rinne, Filippa Bertilsson, Ram Kumar Selvaraju, Anja C Lundgren Mortensen, Cecilia Lindskog, Marika Nestor (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13544198.txt.
Description
Amanda Gustafsson and seven co-authors test a radioactive drug aimed at CD44v6 in pancreatic cancer, alone and with chemotherapy, in preclinical work. This cancer is fiercely aggressive, and the target sits high on many tumors. The study came out in twenty twenty-six.
Cell lines were checked for the target, drug binding, and chemo response. Mice with grafted tumors got the drug, chemo, or both. Harm was tracked by weight, blood, and organ checks. Tumor uptake ran very high. Growth slowed in step with dose, and some tumors vanished fully at set doses. Pairing with a chemo drug also cleared some tumors.
Catalog record
| CREATOR | Amanda Gustafsson, Hedvig Svedberg, Sara S Rinne, Filippa Bertilsson, Ram Kumar Selvaraju, Anja C Lundgren Mortensen, Cecilia Lindskog, Marika Nestor |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |